Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2018

Schiefer Mart, Hendriks Lizza E L, Dinh Trang, Lalji Ulrich, Dingemans Anne-Marie C

Abstract excerpt

An increasing number of tyrosine kinase inhibitors (TKIs) are available for the treatment of non-small cell lung cancer (NSCLC). QT prolongation is one of the known, but relatively rare, adverse events of several TKIs (e.g. osimertinib, crizotinib, ceritinib). Screening for QT prolongation in (high risk) patients is advised for these TKIs. When a QT prolongation develops, the physician is challenged with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Drug Monitoring

Share to Electrocardiography

Share to Fatal Outcome

Share to Long QT Syndrome

Share to Piperazines

Source

Identifiers

PMID: 29413968
DOI: 10.1016/j.ejca.2017.12.011

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.PMID 29413968Read ↗

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportSemantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read ↗

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.Semantic proximity Read ↗

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Semantic proximity Read ↗

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read ↗

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin.Semantic proximity Read ↗

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.Semantic proximity Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.Semantic proximity Read ↗

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.Semantic proximity Read ↗

Successful Management of Osimertinib-Induced Heart Failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.